Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Global Health Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Front Cell Infect Microbiol. 2022 Jul 22;12:917282. doi: 10.3389/fcimb.2022.917282. eCollection 2022.
Multidrug therapy (MDT) has been successfully used in the treatment of leprosy. However, although patients are cured after the completion of MDT, leprosy reactions, permanent disability, and occasional relapse/reinfection are frequently observed in patients. The immune system of multibacillary patients (MB) is not able to mount an effective cellular immune response against . Consequently, clearance of bacilli from the body is a slow process and after 12 doses of MDT not all MB patients reduce bacillary index (BI). In this context, we recruited MB patients at the uptake and after 12-month of MDT. Patients were stratified according to the level of reduction of the BI after 12 doses MDT. A reduction of at least one log in BI was necessary to be considered a responder patient. We evaluated the pattern of host gene expression in skin samples with RNA sequencing before and after MDT and between samples from patients with or without one log reduction in BI. Our results demonstrated that after 12 doses of MDT there was a reduction in genes associated with lipid metabolism, inflammatory response, and cellular immune response among responders (, and ). Also, by comparing MB patients with lower BI reduction versus responder patients, we identified high expression of , and before MDT. From the most differentially expressed genes, we observed that MDT modulates pathways related to immune response and lipid metabolism in skin cells from MB patients after MDT, with higher expression of genes like , that are associated with cholesterol metabolism in the group with the worst response to treatment. Altogether, the data presented contribute to elucidate gene signatures and identify differentially expressed genes associated with MDT outcomes in MB patients.
多药疗法(MDT)已成功用于麻风病的治疗。然而,尽管患者在 MDT 完成后痊愈,但仍经常观察到麻风反应、永久性残疾和偶尔的复发/再感染。多菌型患者(MB)的免疫系统无法针对 产生有效的细胞免疫反应。因此,从体内清除杆菌是一个缓慢的过程,在接受 12 剂 MDT 后,并非所有 MB 患者的杆菌指数(BI)都会降低。在这种情况下,我们在纳入和 MDT 后 12 个月时招募了 MB 患者。根据 MDT 后 12 剂时 BI 降低水平对患者进行分层。BI 降低至少一个对数被认为是应答者患者。我们使用 RNA 测序评估了 MDT 前后和 BI 降低对数患者之间的皮肤样本中的宿主基因表达模式。我们的结果表明,在接受 12 剂 MDT 后,应答者(和)的脂质代谢、炎症反应和细胞免疫反应相关基因减少。此外,通过比较 BI 降低较少的 MB 患者与应答者患者,我们发现 MDT 前 和 表达较高。在差异表达最多的基因中,我们观察到 MDT 调节了 MDT 后 MB 患者皮肤细胞中与免疫反应和脂质代谢相关的途径,在对治疗反应最差的组中,与胆固醇代谢相关的基因 、 和 表达较高。总的来说,所提供的数据有助于阐明基因特征,并确定与 MB 患者 MDT 结果相关的差异表达基因。